Jeonju-si, South Korea

Chong Hyon Ryu


Average Co-Inventor Count = 19.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2011

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Chong Hyon Ryu in Pharmaceutical Chemistry

Introduction

Chong Hyon Ryu is a notable inventor based in Jeonju-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that serve as vanilloid receptor antagonists. His work aims to address various medical conditions, enhancing the quality of life for many patients.

Latest Patents

Chong Hyon Ryu holds a patent for "Compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same." This invention relates to novel compounds that act as antagonists to the vanilloid receptor (Vanilloid Receptor 1; VR1; TRPV1). The pharmaceutical composition developed through this patent is designed to prevent or treat a range of diseases, including pain, migraine, arthralgia, neuralgia, neuropathies, nerve injury, skin disorders, urinary bladder hypersensitivity, irritable bowel syndrome, respiratory disorders, and inflammatory diseases.

Career Highlights

Chong Hyon Ryu is associated with Amorepacific Corporation, a leading company in the beauty and health industry. His role at the company allows him to leverage his expertise in pharmaceutical innovations to contribute to the development of effective health solutions.

Collaborations

Throughout his career, Chong Hyon Ryu has collaborated with esteemed colleagues such as Young-Ger Suh and Hee-Doo Kim. These collaborations have fostered a productive environment for innovation and research in pharmaceutical sciences.

Conclusion

Chong Hyon Ryu's contributions to pharmaceutical chemistry, particularly through his patent on vanilloid receptor antagonists, highlight his commitment to advancing medical science. His work continues to pave the way for new treatments that can significantly improve patient care.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…